The availability of direct-acting antivirals (DAAs) has transformed the treatment scenario in human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients with sustained virological response (SVR) results over 90%-95%. In the peritransplant setting, there are few real-world experiences in treating patients with HIV/HCV coinfection.
Methods
We conducted a retrospective and observational case-control study in a single center, Hospital Universitario y Politécnico La Fe (Valencia, Spain), which was approved by the local institutional review board. All HIV/HCV-coinfected patients who initiated HCV antiviral treatment with interferon (IFN)-free regimens from March 2014 to March 2016 either on the WL for liver transplantation (LT) or after LT were included. Each HIV/HCV-coinfected patient was matched with 2 HCV-monoinfected patients by HCV genotype (when possible), fibrosis stage, and treatment regimen, and, in the case of cirrhosis, with Model for End-Stage Liver Disease (MELD) and Child-Pugh scores.
Treatment regimen choice was based on drug availability at each time point, as given by compassionate-use programs and progressive drug commercialization.
Data were collected per local standard of care and at different time points: baseline (pretreatment), ontreatment (weeks 4, 12, and 24), and after treatment (weeks 4, 12, 24, and 48). Patients were followed up to 2 years since treatment initiation.
For the descriptive analysis, quantitative variables are presented as median and/or mean and interquartile ranges (IQRs) or range, while categorical variables are presented as frequencies and percentages. Differences between categorical variables were assessed by chisquare test. Continuous variables were compared using the Student t test. All data were analyzed using STATA, version 12 (Stata Corp., College Station, TX).
Results
Nine HIV/HCV-coinfected patients on the WL for LT were included, matched to 18 HCV-monoinfected patients in the control group. A total of 14 HIV/HCVcoinfected LT recipients with HCV recurrence receiving 15 antiviral treatments (1 patient was retreated after relapse) were included, matched to 30 HCVmonoinfected patients in the control group. Baseline features of pretransplant and posttransplant patients are summarized in Table 1 . Notably, 11% of patients included (8/45) received a sofosbuvir (SOF) + ribavirin (RBV) regimen, which is not currently the recommended standard of care but was the only available regimen at the moment (see Table 1 ).
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TreaTMenT viroLoGiCaL anD CLiniCaL eFFiCaCY
Before Transplant
Rates for the sustained virological response at 12 weeks (SVR12) were higher in the monoinfected group (89%, n = 16/18) versus the coinfected group (67%, n = 6/9) (P = 0.16; see Fig. 1 ). Lower efficacy rates in the coinfected group correspond to 2 nonresponses in patients with genotype 4 treated with SOF + RBV, which is a suboptimal regimen for this genotype, especially in the case of decompensated cirrhosis, but was the only available regimen at the time. Both of these patients were successfully retreated in the post-LT setting with optimal DAA combination therapies. In the HCVmonoinfected group, there was 1 viral relapse after treatment in a genotype 1a patient who received a 12-week SOF/ledipasvir (LDV) + RBV treatment. This patient was successfully retreated after LT. Treatment efficacy rates are represented in Fig. 1 , comparing all patients to patients receiving optimal regimens (ie, excluding those treated with SOF + RBV).
As a result of successful antiviral treatment, at week 12 the posttreatment MELD score improved in 33% of patients in each group. Regarding ChildPugh score, 50% of monoinfected patients and 33% of coinfected patients experienced improvement (P = 0.41). Importantly, this improvement was maintained after 2 years of follow-up for both MELD and Child-Pugh scores. As a result of hepatic function improvement, 8 patients were removed from the WL or delisted (3 HIV/HCV-coinfected and 5 HCV-monoinfected patients).
after Transplant
Treatment was highly and equally effective in the posttransplant setting in both groups of patients with SVR12 rates of 93% (n = 14/15) in the coinfected group and 93% (n = 28/30) in the monoinfected group. There was 1 viral relapse in the coinfected group in a patient treated with SOF + simeprevir (SMV) + RBV for 12 weeks, which was successfully retreated with SOF/LDV + RBV for 24 weeks.
TreaTMenT saFeTY Before Transplant
In general, antiviral treatment was well tolerated. The most frequent adverse event in both groups was anemia, defined as hemoglobin levels below 10 g/dL, occurring in approximately half of the patients in both groups.
Infections were significantly more frequent in the coinfected group (67% versus 28%; P = 0.05). The most frequent infection in both groups was spontaneous bacterial peritonitis (83% versus 75%). Hepatic decompensations during treatment were equally frequent in both groups (44%).
One coinfected and 2 monoinfected patients died due to HCC progression while on the WL. Two of these patients had extra-Milan HCC who progressed even after transarterial chemoembolization was performed, in the setting of long WL time. The remaining patient presented with a concomitant extrahepatic lymphoma with HCC progression and was therefore excluded from the WL.
after Transplant
In the posttransplant setting, anemia was also the most frequent adverse event, present in approximately half of the patients in both groups. Anemia was significantly more frequent in RBV-containing regimens (P < 0.001); no patient with a RBV-free regimen presented with anemia. No allograft rejection episodes occurred either during or after antiviral therapy.
In the posttransplant setting, no coinfected patients died, whereas 3 HCV-monoinfected patients died, 2 of them with decompensated graft cirrhosis. One of them died at week 8 of treatment due to hepatic coma (baseline Child-Pugh score C10, baseline MELD score 20), and the other died on week 11 after treatment due to abdominal sepsis (spontaneous bacterial peritonitis) leading to multiorganic failure and death (baseline 
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Child-Pugh score B7, baseline MELD score 13). The other patient died 1 year after treatment completion due to a lymphoma. DDIs between DAA and calcineurin inhibitor (CNI) were easily managed.
One coinfected patient was switched from cyclosporine to tacrolimus before starting a SMV-containing regimen, and another coinfected patient needed a cyclosporine dose reduction before starting antiviral treatment with paritaprevir/ritonavir/ombitasvir + dasabuvir.
Hiv FeaTUres
Regarding combination antiretroviral therapy (cART), the most used regimen was tenofovir/emtricitabine + raltegravir both in the pretransplant (43%) and in the posttransplant setting (50%). Only 1 patient required changes in their cART before starting antiviral treatment because of the lack of information about the interactions of maraviroc with other drugs such as SMV and daclatasvir (DCV) at the time. Regarding DDIs between cART and immunosuppressive therapies as CNI, trough plasma level measurements of CNIs during treatment were equally frequent in both coinfected and monoinfected patients during therapy, with minor adjustments needed.
Regarding immunological status in HIV-infected patients, a trend toward a higher CD4 cell count from baseline to after treatment was observed in LT recipients (293 versus 304, respectively), but not in patients awaiting LT (499 versus 338, respectively), probably in relation to advanced liver disease. Nevertheless, the small number of patients prevents us from drawing any conclusion. HIV viremia was undetectable before starting antiviral treatment in all but 1 patient and remained undetectable during treatment in all patients.
Discussion
This article describes the experience in 1 LT center with DAA in the peritransplant period, and it is the first to compare the efficacy and safety with HCVmonoinfected patients. Our study highlights that IFN-free antiviral therapy in HIV/HCV-coinfected patients awaiting LT or after LT leads to similar safety and efficacy results as those observed in HCVmonoinfected patients in the peritransplant setting.
Regarding antiviral treatment of patients awaiting a LT, a study by Londoño et al. (1) reported 4 patients with compensated cirrhosis and HCC who received IFN-free antiviral treatment, all of them achieving SVR and with no tolerability issues. Recently, an Italian multicenter study (2) reported the results of 24 HIV patients with cirrhosis who were treated during the pretransplant period, of whom 20 were decompensated (Child-Pugh B and C). The overall SVR rate in this cohort was 79%.
In the posttransplant setting, several real-world series of HIV-infected patients have been reported. A study by Grant et al. (3) reported the data of 8 HIVcoinfected LT recipients with mild HCV recurrence 
